A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00076323

Enrollment

Registered

2004-01-21

Start date

2003-12-31

Completion date

2006-11-30

Last updated

2010-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Favism, Glucosephosphate Dehydrogenase Deficiency

Keywords

G6PD, Favism, G6PD Deficiency, hemolysis, drug reaction, drug-induced hemolysis

Brief summary

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Interventions

DRUGPrimaquine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

Inclusion: * Normal clinical evaluation * Willing and able to make all scheduled visits Exclusion: * pregnant or planning pregnancy * Have taken any anti-malarial medication in past month * Positive blood tests for HIV and specific types of hepatitis * Allergic to primaquine

Design outcomes

Primary

Measure	Time frame
Difference in degree of hemolysis of G6PD(-) red blood cells in treated vs untreated matched samples.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026